Giant Biogene Holding Co. Ltd. (HK:2367)
:2367
Top Page
Giant Biogene Holding Co. Ltd.
(2367)
Select Model
Select Model
Rating:66Neutral
Price Target:
HK$35.00
â–˛(23.50% Upside)
Action:ReiteratedDate:12/03/25
Giant Biogene Holding Co. Ltd. has a strong financial foundation with high revenue growth and solid margins, contributing significantly to its score. However, the bearish technical indicators and lack of cash flow data for 2024 pose concerns. The valuation is reasonable, but not compelling enough to offset the technical weaknesses.
Positive Factors
Sustained Revenue Growth
A 57% year-over-year revenue jump reflects structural demand expansion or successful distribution/product scaling. Sustained top-line growth over multiple periods supports reinvestment capacity, makes future margin expansion likelier, and underpins long-term operating leverage.
Negative Factors
Missing 2024 Cash Flow Data
Absence of 2024 cash flow figures limits visibility into current operating cash conversion and liquidity trends. That gap weakens assessment of dividend sustainability, capex funding capacity and working capital needs, making forecasted free cash generation less certain.
Read all positive and negative factors
Positive Factors
Negative Factors
Sustained Revenue Growth
A 57% year-over-year revenue jump reflects structural demand expansion or successful distribution/product scaling. Sustained top-line growth over multiple periods supports reinvestment capacity, makes future margin expansion likelier, and underpins long-term operating leverage.
Read all positive factors
Giant Biogene Holding Co. Ltd. (2367) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$29.97B
Dividend Yield1.84%
Average Volume (3M)12.22M
Price to Earnings (P/E)16.8
Beta (1Y)1.16
Revenue Growth36.70%
EPS Growth22.26%
CountryHK
Employees1,758
SectorConsumer Defensive
Sector Strength42
IndustryHousehold & Personal Products
Share Statistics
EPS (TTM)0.77
Shares Outstanding1,070,904,000
10 Day Avg. Volume16,417,830
30 Day Avg. Volume12,220,358
Financial Highlights & Ratios
PEG Ratio0.56
Price to Book (P/B)6.60
Price to Sales (P/S)8.47
P/FCF Ratio26.15
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$39.70Price Target Upside40.08% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)1.88
Revenue Forecast (FY)HK$6.17B
Giant Biogene Holding Co. Ltd. Business Overview & Revenue Model
Company Description
Giant Biogene Holding Co., Ltd., an investment holding company, engages in the research, development, manufacture, and sale of bioactive material-based beauty and health products in the People's Republic of China. It also manufactures rare ginseno...
How the Company Makes Money
Giant Biogene generates revenue primarily through the sale of its biogeneric drugs and therapeutic products. The company's revenue model is centered around the development and commercialization of biosimilars, which are biologic medical products h...
Giant Biogene Holding Co. Ltd. Financial Statement Overview
Summary
Income Statement
87
Very Positive
Balance Sheet
78
Positive
Cash Flow
65
Positive
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 6.11B | 5.54B | 3.52B | 2.36B | 1.55B | 1.19B |
| Gross Profit | 5.00B | 4.55B | 2.95B | 2.00B | 1.35B | 1.01B |
| EBITDA | 2.60B | 2.31B | 1.78B | 1.21B | 933.64M | 826.02M |
| Net Income | 2.26B | 2.06B | 1.45B | 1.00B | 828.13M | 826.45M |
Balance Sheet | ||||||
| Total Assets | 11.29B | 8.04B | 4.97B | 3.14B | 7.88B | 2.65B |
| Cash, Cash Equivalents and Short-Term Investments | 8.86B | 5.86B | 3.78B | 2.20B | 7.26B | 1.96B |
| Total Debt | 6.95M | 6.71M | 2.73M | 2.59M | 0.00 | 0.00 |
| Total Liabilities | 2.10B | 918.14M | 602.03M | 301.19M | 6.86B | 2.19B |
| Stockholders Equity | 9.18B | 7.11B | 4.36B | 2.83B | 1.02B | 458.00M |
Cash Flow | ||||||
| Free Cash Flow | 1.47B | 1.79B | 1.42B | 778.39M | 581.21M | 757.79M |
| Operating Cash Flow | 1.83B | 2.04B | 1.65B | 931.64M | 692.40M | 834.12M |
| Investing Cash Flow | -688.87M | -1.11B | -527.28M | -858.74M | 1.56B | -521.12M |
| Financing Cash Flow | 1.25B | 582.95M | 51.81M | -5.79B | 4.48B | -17.52M |
Giant Biogene Holding Co. Ltd. Technical Analysis
Negative
28.34
Price Trends
31.82
Negative
34.02
Negative
44.19
Negative
Market Momentum
-1.05
Positive
38.36
Neutral
21.81
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2367, the sentiment is Negative. The current price of 28.34 is below the 20-day moving average (MA) of 29.89, below the 50-day MA of 31.82, and below the 200-day MA of 44.19, indicating a bearish trend. The MACD of -1.05 indicates Positive momentum. The RSI at 38.36 is Neutral, neither overbought nor oversold. The STOCH value of 21.81 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:2367.
Giant Biogene Holding Co. Ltd. Peers Comparison
UnderperformOutperform
Sector (62)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
71 Outperform | HK$32.43B | 11.55 | 11.65% | 5.36% | -3.48% | -24.11% | |
66 Neutral | HK$29.97B | 16.77 | 19.93% | 1.84% | 36.70% | 22.26% | |
64 Neutral | HK$3.09B | 12.04 | 6.65% | 5.90% | 9.72% | -10.15% | |
62 Neutral | $20.33B | 14.63 | -3.31% | 3.23% | 1.93% | -12.26% | |
61 Neutral | HK$20.15B | 24.23 | 42.05% | 2.53% | 20.78% | 18.37% | |
48 Neutral | HK$981.03M | 92.72 | -12.38% | ― | 39.29% | -71.82% | |
44 Neutral | HK$17.41B | -43.19 | -4.30% | 5.00% | 2.79% | -170.67% |
* Consumer Defensive Sector Average
HK:2367
Giant Biogene Holding Co. Ltd.
28.34
-31.19
-52.39%
HK:1044
Hengan International Group Co
27.94
9.12
48.44%
HK:0157
Natural Beauty Bio-Technology
0.49
<0.01
1.03%
HK:6601
Cheerwin Group Limited
2.32
0.47
25.34%
HK:2145
Shanghai Chicmax Cosmetics Co., Ltd. Class H
50.60
8.76
20.94%
HK:6993
Blue Moon Group Holdings Ltd.
2.97
-0.41
-12.13%
Giant Biogene Holding Co. Ltd. Corporate Events
Giant Biogene Wins China Approval for World-First Collagen–Hyaluronate Skin Implant
Jan 15, 2026
Giant Biogene Holding Co., Ltd. announced that its wholly owned subsidiary Shaanxi Giant Biotechnology has obtained a Medical Device Registration Certificate in China for a new product, the Recombinant Type I α1 Subtype Collagen and Sodium Hy...
Giant Biogene Announces Share Repurchase Plan to Enhance Value
Dec 2, 2025
Giant Biogene Holding Co., Ltd has announced its intention to repurchase up to 103,590,400 shares, representing 10% of its issued shares, under a Share Repurchase Mandate approved by shareholders. This move, financed by the company’s own fun...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.